Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 75,054 | 93,120 | 203,434 | 288,640 | 181,381 |
| Marketable Securities | 179,820 | 368,214 | 136,246 | 133,893 | 165,692 |
| Receivables | 144,155 | 165,497 | 148,932 | 140,877 | 87,332 |
| Inventories | 77,408 | 91,541 | 85,959 | 48,325 | 26,628 |
| TOTAL | $493,113 | $734,151 | $601,590 | $630,417 | $472,644 |
| Non-Current Assets | |||||
| PPE Net | 13,530 | 15,173 | 16,955 | 37,824 | 17,068 |
| Investments And Advances | 16,617 | 93,896 | 119,166 | 350,359 | 591,773 |
| Intangibles | 716,908 | 819,482 | 902,209 | 442,253 | 24,840 |
| Other Non-Current Assets | 37,505 | 39,806 | 49,232 | 43,249 | 53,957 |
| TOTAL | $784,560 | $968,357 | $1,087,562 | $873,685 | $687,638 |
| Total Assets | $1,277,673 | $1,702,508 | $1,689,152 | $1,504,102 | $1,160,282 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 79,569 | 96,342 | 117,683 | 78,934 | 49,714 |
| Accrued Expenses | 154,274 | 151,665 | 132,724 | 126,192 | 107,629 |
| Other current liabilities | 56,353 | 37,983 | 64,972 | 39,982 | 3,244 |
| TOTAL | $290,196 | $687,958 | $315,379 | $245,108 | $160,587 |
| Non-Current Liabilities | |||||
| aiOther Non-Current Liabilities | 40,998 | 78,537 | 472,567 | 478,921 | 404,267 |
| TOTAL | $65,961 | $128,346 | $557,922 | $514,136 | $404,267 |
| Total Liabilities | $356,157 | $816,304 | $873,301 | $759,244 | $564,854 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 54,735 | 54,377 | 53,386 | 52,923 | 52,534 |
| Common Shares | 55 | 54 | 53 | 53 | 53 |
| Retained earnings | 482,561 | 481,245 | 379,922 | 326,498 | 199,548 |
| Other shareholders' equity | -593 | -3,210 | 1,539 | 8,975 | 7,417 |
| TOTAL | $921,516 | $886,204 | $815,851 | $744,858 | $595,428 |
| Total Liabilities And Equity | $1,277,673 | $1,702,508 | $1,689,152 | $1,504,102 | $1,160,282 |